Success Metrics

Active Trials
5(71%)

Phase Distribution

Ph early_phase_1
7
100%

Phase Distribution

7

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
7(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Other(2)

Detailed Status

Recruiting5
unknown2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
5
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 17 (100.0%)

Trials by Status

recruiting571%
unknown229%

Recent Activity

5 active trials
Showing 5 of 7
recruitingearly_phase_1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research

NCT06711146
recruitingearly_phase_1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

NCT06120166
recruitingearly_phase_1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

NCT06716164
recruitingearly_phase_1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

NCT06393335
recruitingearly_phase_1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

NCT06277011
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06711146Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research

Recruiting
NCT06120166Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Recruiting
NCT06716164Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

Recruiting
NCT06393335Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Recruiting
NCT06277011Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Recruiting
NCT05747157Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

Unknown
NCT05715606Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7